FDA Sends 30 Warning Letters to Telehealth Companies Over Compounded GLP-1 Marketing on March 06, 2026 claims Glucagon-Like Peptide 1 semaglutide Telemedicine United States Food and Drug Administration warning letters +
Legal Pressure Escalates as FDA Intensifies Crackdown on Direct-to-Consumer Pharma Advertising on October 03, 2025 Direct-to-Consumer Advertising enforcement Legal Challenges pharmaceutical advertising crackdown prescription drug ads Preventive monitoring United States Food and Drug Administration warning letters +